TO THE EDITOR
The therapeutic effect of the chimeric anti-CD20 IgG1 rituximab (Mabthera, Rituxan) which is widely used in the treatment of B-cell non-Hodgkin's lymphomas involves the triggering of Fcg receptor-positive effector cells and/or the activation of complement. 1 The clinical value in follicular lymphoma of polymorphisms of the activating members of the FcgR family, FcgRIIIA (CD16) and FcgRIIA (CD32) expressed on NK and macrophages, suggests that antibody-dependent cell-mediated cytotoxicity (ADCC) may be the major effector mechanism. 2, 3 We have shown that, although downregulated in reactive germinal center B cells, FcgRIIB is expressed by one-fifth of diffuse large B-cell lymphomas (DLBCL). 4 Expression of FcgRIIB on tumor cells could interfere with rituximab action. It may bind the Fc portion of the therapeutic antibody and thus compete for binding with the activating FcgR or with complement which are required for ADCC and CDC, respectively. In addition, FcgRIIB being an inhibitory receptor, 5 its expression may have a direct negative effect on tumor cells upon ligation with immune complexes. To address the questions of the prognostic impact of FcgRIIB expression and its potential influence on rituximab efficacy, we have investigated retrospectively 234 patients included in the LNH-98.5 from the GELA (Groupe d'Etude des Lymphomes de l'Adulte) which has shown that the combination of rituximab and CHOP (R-CHOP) was more effective than CHOP alone. 6 From the 399 patients included in the LNH-98.5 trial, Bcl-2 expression has been previously analyzed in a subgroup of 292 patients, showing that rituximab overcomes resistance to chemotherapy linked to Bcl-2 overexpression. 7 Among this subgroup, immunohistochemical analysis was performed in 234 patients on deparaffinized and microwave pretreated slides, as previously described. 4 Analysis of FcgRIIB expression was performed without knowledge of the clinical data, all positive and doubtful cases being independently analyzed by two pathologists. Samples were considered as positive when at least 10% of tumor cells showed a strong membrane staining. However, results led to a clear-cut positive pattern, with the majority of tumor cells strongly positive at their plasma membrane.
Among the 234 cases, 42 (18%) showed a strong plasma membrane expression of FcgRIIB ( Figure 1 ) on tumor cells (FcgRIIB þ ). FcgRIIB expression was imbalanced within the two arms of treatment, the FcgRIIB þ cases being more frequent in the R-CHOP arm (31/129, 24%) than in the CHOP one (11/105, 11%) (P ¼ 0.007). This imbalance was even more obvious in the stage II subgroup, since 11 out of the 13 FcgRIIB þ cases (85%) received R-CHOP. This imbalance not explicable by a systematic error since the series was issued from a randomized trial and the slides analyzed randomly, without knowledge of clinical data or arm of treatment. There was no linkage between FcgRIIB expression and Bcl-2 (P ¼ 0.3). Similarly, no significant association has been shown between FcgRIIB expression and the other clinical or biological parameters (detailed in Table 1 ).
FcgRIIB expression had no influence on response to therapy (Table 1) nor on survival duration in univariate analysis (median follow-up: 37 months). In the whole population, the 2-year survival estimates were 64% (confidence interval (CI 95% 57-71) vs 67% (CI 95% 52-81) for overall survival (OS) (P ¼ 0.58) and 49% (CI 95% 42-56) vs 55% (CI 95% 40-70) for event-free survival (EFS) (P ¼ 0.38), when comparing FcgRIIB-and FcgRIIB þ cases, respectively. Also, there was no prognostic impact when we analyzed separately both treatment arms. The 2-year OS was 59% (CI 95% 49-68) for FcgRIIB-and 55% (CI 95% 25-84) for FcgRIIB þ cases (P ¼ 0.68) in the group of patients who received CHOP. For R-CHOP arm, the 2-year OS was 69% (CI 95% 60-79) Correspondence for FcgRIIB-and 71% (CI 95% 55-87) for FcgRIIB þ cases (P ¼ 0.58). The better outcome related to the addition of rituximab to CHOP was not modified by the expression of FcgRIIB on tumor cells (Figure 1 ). When treatment arm and FcgRIIB expression were entered in the multivariate Cox model, R-CHOP vs CHOP retained its favorable prognostic impact (P ¼ 0.05 for OS; Po0.0001 for EFS), whereas FcgRIIB status was not significantly related with outcomes (P ¼ 0.8 for OS; P ¼ 0.9 for EFS).
In this study, we confirm in a large series of patients that FcgRIIB, the only FcgR protein present on normal B cells, is expressed on 18% of DLBCL. Because FcgRIIB was absent in reactive germinal center B cells and high expression of FcgRII mRNA was associated with the activated B-like subgroup of DLCBL of poor prognosis, 4 we addressed the question of the prognostic impact of FcgRIIB expression in DLBCL. By an immunohistochemical approach, we found no significant relationship between FcgRIIB protein expression on tumor cells and prognosis of patients. Several hypotheses may explain this discrepancy. In contrast to immunohistochemistry, microarrays analyze the whole tissue without distinction between tumor cells and FcgRIIB-positive reactive cells, such as macrophages and plasma cells. In addition, FcgRIIB expression at the cell surface may not be correlated with mRNA detection since FcgRIIB can be released as soluble form. 8 In conclusion, we have found no prognostic impact of FcgRIIB status in the limit of our series, including 234 DLBCL. Most importantly, our study shows that the favorable impact of the combination R-CHOP on patient's outcome in DLBCLs is not impaired by 
